Tempest Therapeutics, Inc. — Director's Dealing 2016

Mar 15, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2016-03-11

Reporting Person: Dipp Michelle (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-03-11	Common Stock	P	132732	$7.50	Acquired	132732	Indirect
2016-03-14	Common Stock	P	30000	$8.0534	Acquired	162732	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	971921	Direct

Footnotes

F1: This Form 4 reflects the purchase of an aggregate of 162,732 shares purchased by Longwood Fund III LP in the market. The securities in this line are held directly by Longwood Fund III LP. Longwood Fund III GP, LLC is the general partner of Longwood Fund III LP. Voting and investment power with respect to the shares held by Longwood Fund III LP are vested in Richard Aldrich, Michelle Dipp, M.D., Ph.D. and Christoph Westphal, M.D., Ph.D. (collectively, the "Managers"), the managers of Longwood Fund III GP, LLC. Each of the Managers disclaims beneficial ownership of the shares held by Longwood Fund III LP, except to the extent of their respective pecuniary interest therein, and the inclusion of these shares in the report shall not be deemed an admission of beneficial ownership of the shares for the purposes of Section 16 or for any other purpose.

F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.70 to $8.10, inclusive. The Reporting Person undertakes to provide OvaScience, Inc., any security holder of OvaScience, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges sent forth in this footnote.